World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4065)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

HTML

2601

Figures (1-7)

232

Sum=2910

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

225

Download

418

Sum=643

Publishing Process of This Article

Item

Count

Browse

109

Download

255

Sum=364

Jul 28, 2024 (publication date) through Apr 3, 2025

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Koizumi A, Kaji K, Nishimura N, Asada S, Matsuda T, Tanaka M, Yorioka N, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Akahane T, Yoshiji H. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease. World J Gastroenterol 2024; 30(28): 3428-3446 [PMID: 39091710 DOI: 10.3748/wjg.v30.i28.3428]
URL:	https://www.wjgnet.com/1007-9327/full/v30/i28/3428.htm

Number	Citing Articles
1	Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng. Novel intervention for alcohol-associated liver disease. World Journal of Gastroenterology 2024; 30(39): 4308-4312 doi: 10.3748/wjg.v30.i39.4308 Abstract(281) \| Core Tip(265) \| Full Article(HTML)(1063) \| Full Article with Cover (PDF)-1044K(43) \| Audio-316K(3) \| Peer-Review Report-178K(32) \| Answering Reviewers-82K(25) \| Full Article (PDF)-787K(69) \| Full Article (XML)-76K(33) \| Times Cited (0) \| Total Visits (2505) \| Open
2	Xin-Yang Zhang, Qin-Jun-Jie Chen, Feng Zhu, Min Li, Dan Shang. Dual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease?. World Journal of Gastroenterology 2024; 30(37): 4163-4167 doi: 10.3748/wjg.v30.i37.4163 Abstract(254) \| Core Tip(222) \| Full Article(HTML)(1145) \| Full Article with Cover (PDF)-1010K(61) \| Audio-369K(8) \| Peer-Review Report-195K(29) \| Answering Reviewers-217K(29) \| Full Article (PDF)-388K(61) \| Full Article (XML)-65K(40) \| Times Cited (1) \| Total Visits (2218) \| Open
3	Wei-Tong Cui, Hua-Ru Xue, Dian-Fang Wei, Xiao-Yu Feng, Kai Wang. Prospects of elafibranor in treating alcohol-associated liver diseases. World Journal of Gastroenterology 2025; 31(2): 99549 doi: 10.3748/wjg.v31.i2.99549 Abstract(173) \| Core Tip(174) \| Full Article(HTML)(706) \| Full Article with Cover (PDF)-640K(38) \| Audio-1553K(3) \| Peer-Review Report-208K(29) \| Answering Reviewers-107K(36) \| Full Article (PDF)-389K(72) \| Full Article (XML)-102K(38) \| Times Cited (0) \| Total Visits (1565) \| Open
4	Jordi Gratacós-Ginès, Edilmar Alvarado-Tapias, David Martí-Aguado, Hugo López-Pelayo, Ramón Bataller, Elisa Pose. Diagnosis and Management of Early Stages of ALD. Seminars in Liver Disease 2025; doi: 10.1055/a-2541-2892
5	Manman Hou, Pin Song, Yue Chen, Xiaoran Yang, Pengnan Chen, Aizhi Cao, Yingdong Ni. Bile acids supplementation improves colonic mucosal barrier via alteration of bile acids metabolism and gut microbiota composition in goats with subacute ruminal acidosis (SARA). Ecotoxicology and Environmental Safety 2024; 287: 117313 doi: 10.1016/j.ecoenv.2024.117313
6	Hang Zhang, Xuan Dong, Lei Zhu, Fu-Shan Tang. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World Journal of Gastroenterology 2024; 30(40): 4393-4398 doi: 10.3748/wjg.v30.i40.4393 Abstract(274) \| Core Tip(253) \| Full Article(HTML)(1645) \| Full Article with Cover (PDF)-738K(47) \| Audio-1530K(5) \| Peer-Review Report-220K(31) \| Answering Reviewers-87K(32) \| Full Article (PDF)-406K(75) \| Full Article (XML)-92K(34) \| Times Cited (2) \| Total Visits (2691) \| Open
7	Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi, Issa S Al-Amri. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World Journal of Biological Chemistry 2025; 16(1): 104535 doi: 10.4331/wjbc.v16.i1.104535 Abstract(77) \| Core Tip(74) \| Full Article(HTML)(683) \| Full Article with Cover (PDF)-2137K(58) \| Audio-528K(5) \| Peer-Review Report-316K(61) \| Answering Reviewers-330K(52) \| Full Article (PDF)-1962K(37) \| Full Article (XML)-106K(18) \| Times Cited (0) \| Total Visits (1584) \| Open
8	Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Ashok Iyaswamy. Peroxisome proliferator-activated receptor agonists: A new hope towards the management of alcoholic liver disease. World Journal of Gastroenterology 2024; 30(35): 3965-3971 doi: 10.3748/wjg.v30.i35.3965 Abstract(288) \| Core Tip(316) \| Full Article(HTML)(1337) \| Full Article with Cover (PDF)-668K(53) \| Audio-1643K(7) \| Peer-Review Report-204K(36) \| Answering Reviewers-56K(46) \| Full Article (PDF)-394K(80) \| Full Article (XML)-98K(38) \| Times Cited (0) \| Total Visits (2551) \| Open
9	Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng. Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. World Journal of Gastroenterology 2025; 31(3): 98783 doi: 10.3748/wjg.v31.i3.98783 Abstract(212) \| Core Tip(192) \| Full Article(HTML)(988) \| Full Article with Cover (PDF)-776K(34) \| Audio-354K(3) \| Peer-Review Report-302K(24) \| Answering Reviewers-195K(23) \| Full Article (PDF)-356K(61) \| Full Article (XML)-46K(32) \| Times Cited (0) \| Total Visits (1801) \| Open
10	Hong Wei, Li-Xuan Sang, Bing Chang. Elafibranor: A promising treatment for alcohol-associated liver disease?. World Journal of Gastroenterology 2024; 30(39): 4313-4317 doi: 10.3748/wjg.v30.i39.4313 Abstract(254) \| Core Tip(269) \| Full Article(HTML)(819) \| Full Article with Cover (PDF)-641K(33) \| Audio-991K(2) \| Peer-Review Report-219K(25) \| Answering Reviewers-102K(28) \| Full Article (PDF)-383K(52) \| Full Article (XML)-60K(33) \| Times Cited (1) \| Total Visits (1832) \| Open
11	Youtian Zhang, Long Ren, Yinting Tian, Xiaohu Guo, Fengxian Wei, Yawu Zhang. Signaling pathways that activate hepatic stellate cells during liver fibrosis. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1454980
12	Tomoo Yamazaki, Edward E. Cable, Bernd Schnabl. Peroxisome proliferator–activated receptor delta and liver diseases. Hepatology Communications 2025; 9(2) doi: 10.1097/HC9.0000000000000646
13	Luciano Pirola. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. World Journal of Gastroenterology 2025; 31(4): 99312 doi: 10.3748/wjg.v31.i4.99312 Abstract(185) \| Core Tip(169) \| Full Article(HTML)(703) \| Full Article with Cover (PDF)-800K(26) \| Audio-1370K(6) \| Peer-Review Report-640K(22) \| Answering Reviewers-26K(24) \| Full Article (PDF)-483K(53) \| Full Article (XML)-29K(27) \| Times Cited (0) \| Total Visits (1617) \| Open
14	Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo, Zi-Li Zhang. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. World Journal of Gastroenterology 2024; 30(43): 4660-4668 doi: 10.3748/wjg.v30.i43.4660 Abstract(270) \| Core Tip(250) \| Full Article(HTML)(1618) \| Full Article with Cover (PDF)-1222K(35) \| Audio-189K(3) \| Peer-Review Report-330K(37) \| Answering Reviewers-269K(30) \| Full Article (PDF)-868K(76) \| Full Article (XML)-154K(29) \| Times Cited (2) \| Total Visits (3110) \| Open